A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.

Context: No long-term studies have compared centrally acting drugs for treating obesity.

Objective: To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss.

Design And Setting: A prospective, randomized, placebo (PCB)-controlled study conducted at a single academic institution.

Decrease in leptin production by the adipose tissue in obesity associated with severe metabolic syndrome.

Objective: To evaluate the associations between leptinemia and the components of metabolic syndrome (MetS).

Methods: Fifty-one obese adults (9 men; 36.7 +/- 10.

Infeccions as the etiology for obesity.

The role of infection on obesity development has been questioned since the early 1980's. Several studies on animals have shown that physiopathologic mechanisms through which infections can produce obesity do exist. At least eight types of obesity-inducing viruses have been identified in animals, especially poultry and mice.

[Brazilian Consensus on second-generation antipsychotics and metabolic disorders].

Objective: To discuss current aspects of use of antipsychotics considering their metabolic side effects profile, which includes weight gain, dyslipidemias, diabetes and metabolic syndrome. Such metabolic effects increase the risk of mortality by cardiovascular disease, which is the leading cause of death among schizophrenic patients.

Method: A consensus meeting was held, with participation of endocrinologists and psychiatrists specialists in schizophrenia and, based on a literature review, an article was elaborated emphasizing practical and helpful recommendations to clinicians.

Evolutive echocardiographic study of the structural and functional heart alterations in obese individuals after bariatric surgery.

Objective: To evaluate with Doppler echocardiography the reversibility of structural and hemodynamic changes in obeses after bariatric surgery.

Methods: Twenty-three patients (19 women = 82.6%) were studied.

Butyrylcholinesterase activity and metabolic syndrome in obese patients.

Total butyrylcholinesterase activity (EC 3.1.1.

Butyrylcholinesterase and obesity in individuals with the CHE2 C5+ and CHE2 C5- phenotypes.

Objective: To investigate the association between butyrylcholinesterase (BChE) activities (total and band specific) and body mass index (BMI) in obese and nonobese individuals, considering other variables (anthropometric, biochemical and hormonal) and the leanness process.

Subjects: Obese (BMI> or =30 kg/m(2); N=181) and nonobese individuals (N=265), classified according to the CHE2 locus phenotypes, with the obese patients being followed-up when submitted to a weight-loss program.

Measurements: Anthropometric (weight, height, BMI, waist, waist/hip ratio-WHR, triceps and subscapular skinfolds, percentage of body fat and arterial pressures), hormonal (insulin, estradiol-E(2), triiodothyronine-T(3) and thyroxine-T(4)) and biochemical (glucose, total cholesterol, HDL-C, triglycerides, uric acid, urea, creatinine, sodium, potassium and BChE activities) variables.

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

Aim: To determine if obese non-insulin-dependent diabetic patients lose more weight when treated for 24 weeks (6 months) with orlistat (120 mg t.i.d.

The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity.

The aim of the present study was to evaluate the cerebrospinal fluid (CSF)/serum leptin ratio during pharmacological therapy for obesity with centrally and peripherally acting drugs. Thirty-one obese women (mean age, 32.3 +/- 10 yr; body mass index, 38.